Bo Ahrén

101 – 110 of 398

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/af6f8d38-a95b-47b6-9ec5-5f69aa8d0e59?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
…
10
11
12
13
…
40
next »

2014
Mark Pronounced Reduction Of Postprandial Glucagon By Lixisenatide: A Meta-Analysis Of Randomized Clinical Trials.
Ahrén, Bo ^LU ; Gautier, Jean-Francois ; Berria, Rachele ; Stager, William ; Aronson, Ronnie and Bailey, Cliff J (2014) In Diabetes, Obesity and Metabolism 16(9). p.861-868
- Contribution to journal › Article
Mark HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin.
Ahrén, Bo ^LU ; Johnson, Susan L ; Stewart, Murray ; Cirkel, Deborah T ; Yang, Fred ; Perry, Caroline and Feinglos, Mark N (2014) In Diabetes Care 37(8). p.2141-2148
- Contribution to journal › Article
Mark Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors.
Omar, Bilal ^LU and Ahrén, Bo ^LU (2014) In Diabetes 63(7). p.2196-2202
- Contribution to journal › Article
Mark Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
Ahrén, Bo ^LU (2014) In World Journal of Diabetes 5(1). p.40-51
- Contribution to journal › Scientific review
Mark Glucagon clearance is regulated by nutritional state : Evidence from experimental studies in mice
Zhou, Alyssa ; Pacini, Giovanni ; Ahrén, Bo ^LU and D'Argenio, David Z. (2014) In Diabetologia 57(4). p.801-808
- Contribution to journal › Article
2013
Mark Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion.
Ahlkvist, Linda ^LU ; Brown, K and Ahrén, Bo ^LU (2013) In Endocrine Connections 2(2). p.69-78
- Contribution to journal › Article
Mark Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
Monami, M. ; Ahrén, Bo ^LU ; Dicembrini, I. and Mannucci, E. (2013) In Diabetes, Obesity and Metabolism 15(2). p.112-120
- Contribution to journal › Article
Mark Shifting the paradigm of islet inflammation-good guy or bad guy?
Ahrén, Bo ^LU ; Accili, D ; Boitard, C ; Cerasi, E ; Thorens, B and Seino, S (2013) In Diabetes, Obesity and Metabolism 15. p.4-9
- Contribution to journal › Debate/Note/Editorial
Mark Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives.
Ahrén, Bo ^LU (2013) In Diabetes & Metabolism 39(3). p.195-201
- Contribution to journal › Scientific review
Mark Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease
Johansson, Per ^LU ; Aberg, Daniel ; Johansson, Jan-Ove ; Mattsson, Niklas ; Hansson, Oskar ^LU ; Ahrén, Bo ^LU ; Isgaard, Jorgen ; Aberg, N. David ; Blennow, Kaj ^LU and Zetterberg, Henrik , et al. (2013) In Psychoneuroendocrinology 38(9). p.1729-1737
- Contribution to journal › Article

« previous
1
…
10
11
12
13
…
40
next »